Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

• The impact of present disease-modifying treatments (DMTs) in multiple sclerosis (MS) on nerve injury and reactive astrogliosis is still unclear. Therefore, we studied the effect of natalizumab treatment on the release of 2 brain-specific tissue damage markers into cerebrospinal fluid (CSF) in MS patients.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

Adolescent

Adult

Antibodies

Monoclonal

therapeutic use

Axons

pathology

Enzyme-Linked Immunosorbent Assay

Female

Glial Fibrillary Acidic Protein

cerebrospinal fluid

drug effects

Gliosis

chemically induced

prevention & control

Humans

Integrin alpha4

therapeutic use

Longitudinal Studies

Male

Middle Aged

Multiple Sclerosis

Chronic Progressive

cerebrospinal fluid

drug therapy

Multiple Sclerosis

Relapsing-Remitting

cerebrospinal fluid

drug therapy

pathology

Nerve Degeneration

pathology

prevention & control

Neurofilament Proteins

cerebrospinal fluid

drug effects

Recurrence

tau Proteins

cerebrospinal fluid

drug effects

fibrillary acidic protein; placebo-controlled trial; cerebrospinal-fluid; neurofilament light; disease-activity; lesion load; disability; MS; CSF

MEDICINE

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)